Oncology Expert Insights

Greater Flexibility and Improved QOL Represent Key Potential Benefits With Liquid TKI Formulations: With Jonathan Trent, MD, PhD

ByJonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center

August 7th 2026

Jonathan Trent, MD, PhD, discusses the clinically available TKIs for GIST and the potential benefits of liquid TKI formulations for this disease.

Solange Peters, MD, PhD, University Hospital of Lausanne

Positioning PD-L1/VEGF Bispecifics in First-Line Non–Small Cell Lung Cancer: With Solange Peters, MD, PhD

BySolange Peters, MD, PhD

July 31st 2026

Dr Peters discussed the rationale for pairing antiangiogenic activity with checkpoint inhibition upfront in NSCLC, rather than sequencing them.

Biomarker-Driven Shifts Signal the Next Generation of mCRC Therapies: With Tanios S. Bekaii-Saab, MD

ByTanios Bekaii-Saab, MD, FACP

July 30th 2026

Dr Bekaii-Saab discusses the current state of the metastatic colorectal cancer treatment landscape and potential future research directions.

Marlana M. Orloff, MD, the Alexander & Johnston Family Endowed Clinical Director in Uveal Melanoma, and associate professor at Thomas Jefferson University Hospital

Sequencing Systemic and Liver-Directed Therapy in HLA-A*02:01–Negative Metastatic Uveal Melanoma: With Marlana M. Orloff, MD

ByMarlana M. Orloff, MD

July 29th 2026

Dr Orloff discusses the distinct biology of uveal melanoma and why it has historically resisted systemic treatment.

ASCO 2026 ADC Data Clarify Some Strategies and Raise Further Questions for Breast Cancer Care: With Paolo Tarantino, MD, PhD

ByPaolo Tarantino, MD

July 27th 2026

Dr Tarantino discusses practice-informing data regarding antibody-drug conjugates in breast cancer that were presented at the 2026 ASCO Annual Meeting.

FDA Approval Insights: First-Line Sacituzumab Govitecan Plus Pembrolizumab for PD-L1+ TNBC: With Sara M. Tolaney, MD, MPH

BySara M. Tolaney, MD, MPH

July 27th 2026

Dr Tolaney discusses the FDA approval of first-line sacituzumab govitecan plus pembrolizumab for locally advanced or metastatic PD-L1–positive TNBC.

FDA Approval Insights: Orally Disintegrating Nilotinib Tablets for CML: With Jorge E. Cortes, MD; and Elias Jabbour, MD

ByJorge Cortes, MD,Elias Jabbour, MD

July 27th 2026

Dr Cortes and Dr Jabbour discuss the orally disintegrating tablet formulation of nilotinib and its June 2026 FDA approval for patients with CML.

Joshua K. Sabari, MD, assistant professor in the Department of Medicine at NYU Grossman School of Medicine, and director of High Reliability Organization Initiatives at NYU Langone Health’s Perlmutter Cancer Center

Treat Early and Aggressively: Optimizing Small Cell Lung Cancer Management Across the Community Setting: With Joshua K. Sabari, MD

ByJoshua K. Sabari, MD

July 24th 2026

Joshua K. Sabari, MD, discusses the complexities of managing SCLC across both academic and community settings.

Neil D. Gross, MD, FACS, The University of Texas MD Anderson Cancer Center

Navigating Systemic Therapy Selection and Sequencing in Advanced CSCC: With Neil D. Gross, MD, FACS

ByNeil D. Gross, MD, FACS

July 17th 2026

Dr Gross discusses the key biological and clinical distinctions between cutaneous squamous cell carcinoma and basal cell carcinoma.

RECITE Findings Highlight the Potential of Romiplostim to Preserve Chemotherapy Delivery in GI Cancer: With Gerald Soff, MD

ByGerald Soff, MD

July 13th 2026

Gerald Soff, MD, discusses the phase 3 RECITE trial, which evaluated romiplostim for the treatment of persistent chemotherapy-induced thrombocytopenia in patients with GI cancer.

Dissecting INDEPENDENCE Data and the Role of Luspatercept in Myelofibrosis-Associated Anemia: With Claire Harrison, MD

ByClaire Harrison, MD

June 30th 2026

Claire Harrison, MD, discusses data for luspatercept in myelofibrosis-associated anemia from the INDEPENDENCE trial.

Martin Schoen, MD, and Andrew W. Hahn, MD

Treatment Intensification in Vulnerable Populations: ARPI Use in Elderly, Frail, and High-Comorbidity Patients With mCSPC: With Martin Schoen, MD, and Andrew W. Hahn, MD

ByMartin W. Schoen, MD, MPH,Andrew W. Hahn, MD

June 30th 2026

Martin Schoen, MD, and Andrew W. Hahn, MD, discuss ARPI use in elderly, frail, and high-comorbidity patients with mCSPC

Unlocking the Power of ctDNA for Residual Disease, Resistance Monitoring, and Real-Time Treatment Decisions in GI Cancers: With Christopher Lieu, MD

ByChristopher Lieu, MD

June 29th 2026

Christopher Lieu, MD, discusses the evolving clinical role of ctDNA in GI oncology, including MRD-guided treatment decisions and liquid biopsy vs tissue testing in mCRC.

KRAS-Directed Therapy Enters a New Era in Pancreatic Cancer: With Zev A. Wainberg, MD

ByZev A. Wainberg, MD

June 19th 2026

Zev A. Wainberg, MD, discusses the rapidly evolving landscape of KRAS-directed therapy in PDAC from pan-RAS inhibition to KRAS G12D–specific strategies.

As CTCL Staging and Treatment Evolves, Treatment-Associated Rash Remains a Crucial Consideration: With Brad Haverkos, MD

ByBrad Haverkos, MD

June 18th 2026

Brad Haverkos, MD, discusses evolving management and treatment adherence strategies in cutaneous T-cell lymphoma.

Hirsch Matani, MD, Elizabeth Zhang-Velten, MD, PhD, and Binh T. Ngo, MD, discuss radiation and multidisciplinary approaches in skin cancer.

Navigating Radiation, Systemic Therapy, and Multidisciplinary Care in Skin Cancer: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD, PhD; and Binh T. Ngo, MD

ByHirsch Matani, MD,Elizabeth Zhang-Velten, MD, PhD,Binh T. Ngo, MD

June 1st 2026

Hirsch Matani, MD, Elizabeth Zhang-Velten, MD, PhD, and Binh T. Ngo, MD, discuss radiation and multidisciplinary approaches in skin cancer.

Archana Jadhav, MD; Monica Peravali, MD; and Anthony Chi, MD; faculty at the Mid-Atlantic Permanente Medical Group

In-House Molecular Testing in NSCLC Improves Turnaround Time, Tissue Stewardship, and Multidisciplinary Coordination: Featuring Anthony Chi, MD; Monica Peravali, MD; and Archana Jadhav, MD

ByMonica Peravali, MD,Archana Jadhav, MD,Anthony Chi, MD

May 28th 2026

Drs Chi, Peravali, and Jadhav discuss the practical advantages and clinical implications of implementing in-house NGS testing for patients with NSCLC.

Jacob Sands, MD, associate chief of the Lowe Center for Thoracic Oncology, Oncology Medical Director of the International Patient Center, and physician at Dana-Farber Cancer Institute, as well as an assistant professor at Harvard Medical School

Emerging Targets, Second-Line Standards, and Molecular Subtyping Signal a New Era in SCLC Care: With Jacob Sands, MD

ByJacob Sands, MD

May 26th 2026

Dr Sands discusses the rapidly evolving treatment landscape for SCLC.

TKIs Continue to Move Forward and Expand Their Potential in CML: With Michael J. Mauro, MD

ByMichael J. Mauro, MD

May 22nd 2026

Michael J. Mauro, MD, discusses his approach to TKI use in chronic myeloid leukemia and how new FDA approvals inform his practice.

Pedram Razavi, MD, PhD, breast medical oncologist, director, Liquid Biopsy & Genomics, Memorial Sloan Kettering Cancer Center; Dara S. Ross, MD, associate attending pathologist, Memorial Sloan Kettering Cancer Center

Evolving ESR1 Mutation Testing Directions Complicate the Future of Metastatic Breast Cancer Management: With Pedram Razavi, MD, PhD; and Dara S. Ross, MD

ByPedram Razavi, MD, PhD,Dara S. Ross, MD

May 20th 2026

Drs Razavi and Ross note the evolution of ESR1 mutation–directed breast cancer management, including the role of genomic testing at metastatic recurrence.

Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD

ByMike J. Pishvaian, MD, PhD

May 8th 2026

Michael J. Pishvaian, MD, PhD discusses how biomarker-directed strategies, including HER2, CLDN18.2, and KRAS inhibition, are transforming GI cancer care.

FES-PET/CT Reshapes Treatment Planning in Lobular Breast Cancer and Beyond: With Megan Kruse, MD

ByMegan Kruse, MD

April 30th 2026

Megan Kruse, MD, discusses the evolving role of FES-PET/CT in breast cancer, particularly invasive lobular carcinoma.

Alissa Cooper, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School

Treatment Advances in Relapsed SCLC Introduce New Options and Clinical Workflows: With Alissa Cooper, MD

ByAlissa J. Cooper, MD

April 30th 2026

Dr Cooper discusses recent advances that have reshaped the treatment paradigm for small cell lung cancer, particularly in the relapsed setting.

Quinto Gesiotto, MD, discusses optimal ponatinib dosing strategies and evolving TKI sequencing considerations in chronic myeloid leukemia.

Optimizing TKI Sequencing and Ponatinib Dosing Strategies in CML: With Quinto Gesiotto, MD

ByQuinto Gesiotto, MD

April 1st 2026

Quinto Gesiotto, MD, discusses optimal ponatinib dosing strategies and evolving TKI sequencing considerations in chronic myeloid leukemia.

Ticiana Leal, MD, professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, as well as the medical director of the Clinical Trials Office at Winship Cancer Institute

Variability and Innovation in Small Cell Lung Cancer Care: With Ticiana Leal, MD

ByTiciana A. Leal, MD

March 31st 2026

Dr Leal discusses variability in community practice and evolving treatment strategies for patients with small cell lung cancer.

Misty D. Shields, MD, PhD, translational medical oncologist at Indiana University Health in Indianapolis

Community Practice Perspectives: Overcoming Barriers in Small Cell Lung Cancer Care: With Misty D. Shields, MD, PhD

ByMisty D. Shields, MD, PhD

March 30th 2026

Dr Shields discusses the realities of treating patients with SCLC in the community setting and how emerging therapies are shaping care delivery.

John Marshall, MD, chief, Hematology and Oncology, professor, medicine and oncology, director, Otto J Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown Lombardi Comprehensive Cancer Center; Christopher Lieu, MD, professor, medicine, associate director, Clinical Research, co-director, Gastrointestinal Medical Oncology, University of Colorado Anschutz and the University of Colorado Cancer Center

New Trials and Targeted Approaches Advance the Precision of GI Cancer Care: With John Marshall, MD; and Christopher Lieu, MD

ByJohn L. Marshall, MD,Christopher Lieu, MD

March 27th 2026

Drs Marshall and Lieu discuss the clinical relevance of KRAS G12C and pan-RAS inhibitors in the management of pancreatic and colorectal cancers.

Real-World Analyses Help Make Sense of Multiple Approved CAR T-Cell Therapies for ALL: With Jae Park, MD

ByJae Park, MD

March 25th 2026

Jae Park, MD, discusses recent developments for obe-cel and brexu-cel in acute lymphoblastic leukemia.

Real-World Data Support ctDNA-Guided Treatment Strategies in FGFR2-Altered Cholangiocarcinoma: With Marina Baretti, MD

ByMarina Baretti, MD

March 25th 2026

Marina Baretti, MD, discussed the potential utilization of tissue-free ctDNA monitoring for early recurrence detection and treatment monitoring in CCA.

ctDNA Testing At Progression May Help Detect Resistance and Guide Sequencing in GIST: With Drs Jonathan Trent, MD, PhD, and Neeta Somaiah, MD

ByJonathan C. Trent, MD,Neeta Somaiah, MD

March 20th 2026

Jonathan Trent, MD, PhD, and Neeta Somaiah, MD, discuss the importance of identifying genomic drivers and resistance patterns for therapy selection in GIST.

Oncology Expert Insights

Greater Flexibility and Improved QOL Represent Key Potential Benefits With Liquid TKI Formulations: With Jonathan Trent, MD, PhD

Positioning PD-L1/VEGF Bispecifics in First-Line Non–Small Cell Lung Cancer: With Solange Peters, MD, PhD

Biomarker-Driven Shifts Signal the Next Generation of mCRC Therapies: With Tanios S. Bekaii-Saab, MD

Sequencing Systemic and Liver-Directed Therapy in HLA-A*02:01–Negative Metastatic Uveal Melanoma: With Marlana M. Orloff, MD

ASCO 2026 ADC Data Clarify Some Strategies and Raise Further Questions for Breast Cancer Care: With Paolo Tarantino, MD, PhD

FDA Approval Insights: First-Line Sacituzumab Govitecan Plus Pembrolizumab for PD-L1+ TNBC: With Sara M. Tolaney, MD, MPH

FDA Approval Insights: Orally Disintegrating Nilotinib Tablets for CML: With Jorge E. Cortes, MD; and Elias Jabbour, MD

Treat Early and Aggressively: Optimizing Small Cell Lung Cancer Management Across the Community Setting: With Joshua K. Sabari, MD

Navigating Systemic Therapy Selection and Sequencing in Advanced CSCC: With Neil D. Gross, MD, FACS

RECITE Findings Highlight the Potential of Romiplostim to Preserve Chemotherapy Delivery in GI Cancer: With Gerald Soff, MD

Dissecting INDEPENDENCE Data and the Role of Luspatercept in Myelofibrosis-Associated Anemia: With Claire Harrison, MD

Treatment Intensification in Vulnerable Populations: ARPI Use in Elderly, Frail, and High-Comorbidity Patients With mCSPC: With Martin Schoen, MD, and Andrew W. Hahn, MD

Unlocking the Power of ctDNA for Residual Disease, Resistance Monitoring, and Real-Time Treatment Decisions in GI Cancers: With Christopher Lieu, MD

KRAS-Directed Therapy Enters a New Era in Pancreatic Cancer: With Zev A. Wainberg, MD

As CTCL Staging and Treatment Evolves, Treatment-Associated Rash Remains a Crucial Consideration: With Brad Haverkos, MD

Navigating Radiation, Systemic Therapy, and Multidisciplinary Care in Skin Cancer: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD, PhD; and Binh T. Ngo, MD

In-House Molecular Testing in NSCLC Improves Turnaround Time, Tissue Stewardship, and Multidisciplinary Coordination: Featuring Anthony Chi, MD; Monica Peravali, MD; and Archana Jadhav, MD

Emerging Targets, Second-Line Standards, and Molecular Subtyping Signal a New Era in SCLC Care: With Jacob Sands, MD

TKIs Continue to Move Forward and Expand Their Potential in CML: With Michael J. Mauro, MD

Evolving ESR1 Mutation Testing Directions Complicate the Future of Metastatic Breast Cancer Management: With Pedram Razavi, MD, PhD; and Dara S. Ross, MD

Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD

FES-PET/CT Reshapes Treatment Planning in Lobular Breast Cancer and Beyond: With Megan Kruse, MD

Treatment Advances in Relapsed SCLC Introduce New Options and Clinical Workflows: With Alissa Cooper, MD

Optimizing TKI Sequencing and Ponatinib Dosing Strategies in CML: With Quinto Gesiotto, MD

Variability and Innovation in Small Cell Lung Cancer Care: With Ticiana Leal, MD

Community Practice Perspectives: Overcoming Barriers in Small Cell Lung Cancer Care: With Misty D. Shields, MD, PhD

New Trials and Targeted Approaches Advance the Precision of GI Cancer Care: With John Marshall, MD; and Christopher Lieu, MD

Real-World Analyses Help Make Sense of Multiple Approved CAR T-Cell Therapies for ALL: With Jae Park, MD

Real-World Data Support ctDNA-Guided Treatment Strategies in FGFR2-Altered Cholangiocarcinoma: With Marina Baretti, MD

ctDNA Testing At Progression May Help Detect Resistance and Guide Sequencing in GIST: With Drs Jonathan Trent, MD, PhD, and Neeta Somaiah, MD

Trending on OncLive

FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer

Exploring the Rationale for 5-Alpha Reductase Inhibitors in Prostate Cancer Prevention and Active Surveillance

FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy

Dostarlimab Monotherapy Elicits Responses in First-Line PD-L1-Positive HNSCC

The OncFive: Top Oncology Articles for the Week of 8/2